PP
NTLA icon

PDT Partners’s Intellia Therapeutics NTLA Stock Holding History

PDT Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$627K Sell
37,076
-79,565
-68% -$1.11M 0.03% 373
2026
Q1 		$1.5M Sell
116,641
-4,900
-4% -$62.4K 0.09% 282
2025
Q4 		$1.09M Sell
121,541
-35,263
-22% -$485K 0.07% 341
2025
Q3 		$2.71M Sell
156,804
-39,746
-20% -$490K 0.17% 203
2025
Q2 		$1.84M Sell
196,550
-263,696
-57% -$2.17M 0.1% 318
2025
Q1 		$3.27M Buy
460,246
+132,638
+40% +$1.34M 0.23% 141
2024
Q4 		$3.82M Buy
327,608
+312,794
+2,111% +$4.88M 0.34% 83
2024
Q3 		$304K Sell
14,814
-212,406
-93% -$4.9M 0.03% 602
2024
Q2 		$5.09M Buy
227,220
+4,249
+2% +$101K 0.48% 27
2024
Q1 		$6.13M Buy
222,971
+61,974
+38% +$1.72M 0.58% 18
2023
Q4 		$4.91M Buy
160,997
+123,920
+334% +$3.56M 0.54% 28
2023
Q3 		$1.17M Buy
+37,077
New +$1.44M 0.15% 243
2021
Q4 		– Sell
-24,300
Closed -$3.26M – 970
2021
Q3 		$3.26M Sell
24,300
-26,900
-53% -$4.07M 0.23% 192
2021
Q2 		$8.29M Sell
51,200
-2,737
-5% -$213K 0.55% 4
2021
Q1 		$4.33M Sell
53,937
-36,463
-40% -$2.45M 0.31% 107
2020
Q4 		$4.92M Buy
90,400
+6,891
+8% +$250K 0.33% 127
2020
Q3 		$1.66M Sell
83,509
-18,634
-18% -$389K 0.11% 235
2020
Q2 		$2.15M Sell
102,143
-957
-0.9% -$16.3K 0.15% 206
2020
Q1 		$1.26M Buy
103,100
+17,583
+21% +$237K 0.1% 202
2019
Q4 		$1.25M Buy
85,517
+27,317
+47% +$380K 0.08% 245
2019
Q3 		$777K Sell
58,200
-88
-0.2% -$1.4K 0.05% 297
2019
Q2 		$954K Buy
+58,288
New +$916K 0.06% 258
2019
Q1 		– Sell
-87,743
Closed -$1.2M – 481
2018
Q4 		$1.2M Buy
87,743
+17
+0% +$316 0.07% 255
2018
Q3 		$2.51M Sell
87,726
-18,783
-18% -$546K 0.1% 213
2018
Q2 		$2.91M Sell
106,509
-8,745
-8% -$212K 0.11% 209
2018
Q1 		$2.43M Buy
+115,254
New +$2.83M 0.08% 248

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

PDT Partners's NTLA Position: Q2 2026 in Review

PDT Partners reduced its Intellia Therapeutics (NTLA) stake by 68% in Q2 2026, selling an estimated $1.11M and leaving 37,076 shares worth $627K. The position accounts for 0.03% of the portfolio, ranked #373.

PDT Partners first reported a position in NTLA in Q1 2018 and has held it in 26 quarters since. The position peaked at $8.29M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • PDT Partners held 37,076 shares of Intellia Therapeutics worth $627K as of Q2 2026.
  • PDT Partners sold 79,565 Intellia Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Intellia Therapeutics made up 0.03% of PDT Partners's portfolio in Q2 2026, its #373 holding.
  • PDT Partners first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 26 quarters since.
  • PDT Partners's Intellia Therapeutics position peaked at $8.29M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.